ArticleClinicoEconomics and outcomes research : CEOR2017

Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service.

Kirsten Y Westerhout et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.